



ACMG THERAPEUTICS BULLETIN

Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)



Sheri A. Poskanzer¹, Loren D.M. Peña^{2,3}, Zhiyv Niu^{4,5}; on behalf of the ACMG Therapeutics Committee^{6,*}

Disclaimer: This therapeutics bulletin is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this therapeutics bulletin is completely voluntary and does not necessarily assure a successful medical outcome. This therapeutics bulletin should not be considered inclusive of all proper procedures, treatments and tests or exclusive of other procedures, treatments, and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure, treatment, or test, clinicians should apply their own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure, treatment, or test, whether or not it is in conformance with this therapeutics bulletin. Clinicians also are advised to take notice of the date this therapeutics bulletin was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures. Where individual authors are listed, the views expressed may not reflect those of authors' employers or affiliated institutions.

Requests for permissions must be directed to the American College of Medical Genetics and Genomics, as rights holder.

ARTICLE INFO

Article history:

Received 27 January 2023

Accepted 31 January 2023

Available online xxx

Keywords:

Achondroplasia

Linear growth

Pediatrics

Vosoritide

FGFR3.¹ Gain of function variants in *FGFR3* inhibit chondrocyte proliferation and differentiation, which negatively regulates bone growth. Features of achondroplasia may include disproportionate short stature, relative macrocephaly with characteristic facial features, narrowed craniocervical junction, spinal stenosis, additional axial and appendicular skeletal features, restrictive pulmonary disease, obstructive sleep apnea, and more. Developmental delay often occurs, but intelligence is normal in the absence of hydrocephalus or other central nervous system complications.

Background

Achondroplasia is an autosomal dominant genetic diagnosis that occurs secondary to heterozygous pathogenic variants in

Management and Treatment

Recommendations for health supervision and management of individuals with achondroplasia have been published by

This article was a work product of the Therapeutics Committee of the ACMG and the APC was waived. No industry sponsorship was received for this work. The Board of Directors of the American College of Medical Genetics and Genomics approved this bulletin on December 19, 2022.

*Correspondence: ACMG. E-mail address: documents@acmg.net

Affiliations are at the end of the document

doi: <https://doi.org/10.1016/j.gimo.2023.100771>

2949-7744/© 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

multiple groups, including the American Academy of Pediatrics Committee on Genetics.^{2,3} Highlights of current recommendations include baseline imaging of the brain and craniocervical junction, polysomnography, audiology evaluation, surveillance for and treatment of specific manifestations, avoiding circumstances that increase risk of spinal cord compression or may worsen kyphosis, and optimization of functional status.

There were no U.S. Food and Drug Administration (FDA)-approved therapies that were specifically designed for use in patients with achondroplasia before 2021.

Newly Approved Therapy

Indication and approved treatment population

Vosoritide (trade name: VOXZOGO) is a C-type natriuretic peptide analog designed to increase linear growth that has been FDA-approved for treatment in pediatric patients aged 5 years and older with achondroplasia and open epiphyses.⁴ FDA approval was obtained via accelerated approval.

Mechanism of action

Vosoritide is administered via daily subcutaneous injection.⁴ The drug binds to natriuretic peptide receptor-B (NPR-B), which inhibits extracellular signal-regulated kinases 1 and 2 (ERK1/2) in the mitogen-activated protein kinase pathway.⁴ This antagonizes *FGFR3* downstream signaling, which in turn, promotes chondrocyte proliferation and differentiation.

Outcomes and efficacy

The initial phase 3 study was a 52-week, multicenter, randomized, anonymized, and placebo-controlled trial.^{1,4,5} In this study, vosoritide showed an increase in the annualized growth velocity of 1.57 cm/year compared with placebo (95% CI = 1.22-1.93). A 2-year, open-label, phase 3 extension study later demonstrated sustained improvement in growth velocity, including an increase from 5.39 cm/year at 52 weeks to 5.52 cm/year at 104 weeks in the vosoritide-treatment group and an increase from 3.81 cm/year to 5.43 cm/year in children who crossed over from placebo to vosoritide.⁶

Adverse effects and toxicity

The most common adverse reactions noted were injection site reactions and transient hypotension, which could be addressed with a meal and drinking 8 to 12 ounces of fluids.¹ Additional common adverse reactions included arthralgia, dizziness, fatigue, and gastrointestinal concerns

(vomiting, diarrhea, gastroenteritis).⁴ Two subjects discontinued use of vosoritide because of the pain and anxiety with injections. No new adverse effects were detected in the extension study referenced above.⁶

Vosoritide does not have any boxed warnings.

Additional Considerations

Ongoing evaluations of clinical benefit of vosoritide through additional confirmatory clinical trials are being undertaken.^{5,6} Continued FDA approval for vosoritide may be reliant upon further demonstration of clinical benefit.

At the time of this writing, multiple additional interventional clinical trials for achondroplasia were being conducted, each at multiple sites nationally in the United States.⁷ One trial was a phase 2, open-label, dose-escalation and dose-expansion study in children aged 3 to 11 years to evaluate infigratinib, an FGFR 1 to 3-selective tyrosine kinase inhibitor. Another was a phase 2, double-blind, randomized, placebo-controlled, dose-escalation study in children aged 2 to 10 years to evaluate TransCon, a subcutaneous continuous form of C-type natriuretic peptide. A third was an open-label extension study in children aged 15 months to 12 years to evaluate the safety and efficacy of Recifercept, a decoy compound designed to sequester FGFR3 ligands and reduce FGFR3 signaling.⁸

Acknowledgments

The authors extend their thanks to Sandor Roberts for his contributions toward the development of the ACMG Therapeutics Bulletin, a new type of article for our community, including draft creation and submission of this inaugural manuscript.

Conflict of Interest

The authors declare no conflicts of interest.

Affiliations

¹St. Luke's Health System, Boise, ID; ²Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ³Department of Pediatrics, University of Cincinnati, Cincinnati, OH; ⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ⁵Department of Clinical Genomics, Mayo Clinic, Rochester, MN; ⁶American College of Medical Genetics and Genomics, Bethesda, MD

References

1. Legare JM. Achondroplasia. In: Adam MP, Everman DB, Mirzaa GM, et al, eds. *GeneReviews [Internet]*. University of Washington, Seattle; 1993-2023.
2. Hoover-Fong J, Scott CI, Jones MC, COMMITTEE ON GENETICS. Health supervision for people with achondroplasia. *Pediatrics*. 2020;145(6):e20201010. <http://doi.org/10.1542/peds.2020-1010>
3. Pauli RM, Botto LD. Achondroplasia. In: Carey JC, Cassidy SB, Battaglia A, Viskochil D, eds. *Cassidy and Allanson's Management of Genetic Syndromes*. 4th ed. John Wiley & Sons; 2020.
4. U.S. Food and Drug Administration. Highlights of prescribing information. VOXZOGO (vosoritide) for injection, for subcutaneous use. Accessed August 8, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf
5. Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. *Clin Pharmacokinet*. 2022;61(2):263-280. <http://doi.org/10.1007/s40262-021-01059-1>
6. Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. *Genet Med*. 2021;23(12):2443-2447. <http://doi.org/10.1038/s41436-021-01287-7>
7. U.S. National Library of Medicine. Achondroplasia. Accessed August 7, 2022. <https://clinicaltrials.gov/ct2/results?cond=&term=achondroplasia&cntry=&state=&city=&dist=>
8. Gonçalves D, Rignol G, Dellugat P, et al. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. *PLoS One*. 2020;15(12):e0244368. <http://doi.org/10.1371/journal.pone.0244368>